New drug for chronic hives registered in Hong Kong
Patients suffering from chronic hives can enjoy more treatment options, as a new drug targeting the disease has been approved for registration in Hong Kong under the “1+” mechanism, the government said on Monday. Under the mechanism, new drugs that are supported by local clinical data as well as recognised by local experts can apply to get registered in the city by submitting the approval from…
Patients with chronic hives in Hong Kong now have an additional treatment option following the registration of a new drug under the "1+" mechanism, announced by the government on Monday. This innovative drug targets chronic hives and has been approved by an authority in the US, meeting safety, efficacy, and quality standards set by the Registration Committee of the Pharmacy and Poisons Board of Hong Kong.
Chronic spontaneous urticaria, a chronic skin condition causing unpredictable itch and hives, can significantly impact an individual's quality of life. Since the introduction of the "1+" mechanism in 2023, 22 new drugs have been approved for registration in Hong Kong. The Department of Health has received over 910 inquiries from more than 220 pharmaceutical companies interested in registering their products under this streamlined process, which requires approval from a single external drug regulatory authority instead of two.
Written by urgent.news from RTHK English's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- New drug for chronic hives registered in Hong Kong news.rthk.hk
